埃索美拉唑对肝硬化食道静脉曲张预防性套扎治疗后患者肝功能的影响研究  

Effect of esomeprazole on liver function of cirrhotic patients receiving preventive ligation for esophageal varices

作　　者：吕洪敏[1] 向慧玲[1] 张洪生[1] 唐飞[2] 

机构地区：[1]天津市第三中心医院,天津300170 [2]天津医科大学,天津300070

出　　处：《天津药学》2011年第6期28-30,共3页Tianjin Pharmacy

摘　　要：目的:回顾性的分析埃索美拉唑对肝硬化合并食道静脉曲张套扎后患者肝功能的影响。方法:69例肝硬化伴食道静脉曲张进行预防性内镜套扎治疗的病人,套扎后常规的应用质子泵抑制剂(PPI)埃索美拉唑,在应用埃索美拉唑前后分别测定患者肝功能,比较应用埃索美拉唑前后谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil)和凝血酶原活动度(PTA)的变化情况,进而评价埃索美拉对肝硬化病人的安全性。结果:在应用埃索美拉唑前后患者ALT分别为(53.1±6.2)和(36.6±2.9)U/L(P<0.05);AST分别为(76.3±8.4)和(55.1±4.0)U/L(P<0.05);TBil分别为(43.5±4.3)和(36.9±3.9)μmmol/L(P<0.05);PTA分别为(61.5±2.4)%和(60.5±2.5)%(P>0.05)。结论:埃索美拉唑应用在肝硬化伴食道静脉曲张行预防性套扎治疗的病人中,对肝功能不仅没有负面影响,ALT、AST、TBil反而好转,可能与应用保肝药有关,因此埃索美拉唑用于肝硬化食道静脉曲张套扎病人中应用可减少患者套扎术后的再出血,是一种相对较为安全的用药。Objective:To retrospect the effect of esomeprazole on the liver function of cirrhotic patients receiving preventive ligation for esophageal varices.Methods:69 cases with liver cirrhosis combined with esophageal varices received routinely proton pump inhibitor esomeprazole after preventive ligation endoscopy.The liver function was measured before and after the use of esomeprazole,and then the changes in glutamic pyruvic transaminase(ALT)、glutamic oxalacetic transaminase(AST)、total bilirubin(TBil)and prothrombin time activity(PTA) were determined to evaluate the safety of esomeprazole in such patients.Results:The changes of ALT(53.1±6.2) vs(36.6±2.9) U/L(P<0.05),AST(76.3±8.4)vs(55.1±4.0)U/L(P<0.05),TBil(43.5±4.3)vs(36.9±3.9) μmmol/L(P<0.05),PTA(61.5±2.4)%vs(60.5±2.5)%(P>0.05),before and after the use of esomeprazole.Conclusion:The use of esomeprazole in cirrhotic patients with esophageal varices and preventive ligation treatment has no adverse impact on liver function.The use of esomeprazole can reduce rebleeding rate after ligation and is a relatively safe drug.

关 键 词：埃索美拉唑 肝硬化 食道静脉曲张 肝功能 套扎治疗 

分 类 号：R973.1[医药卫生—药品]